Cipla Partners with Qilu Pharma for Keytruda® Biosimilar in the US Kumar Jeetendra | October 12, 2026 Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA) today announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States. As part of the agreement, Qilu …
